EP3720470A4 - Il-2 muteine und deren verwendung - Google Patents

Il-2 muteine und deren verwendung Download PDF

Info

Publication number
EP3720470A4
EP3720470A4 EP18887098.4A EP18887098A EP3720470A4 EP 3720470 A4 EP3720470 A4 EP 3720470A4 EP 18887098 A EP18887098 A EP 18887098A EP 3720470 A4 EP3720470 A4 EP 3720470A4
Authority
EP
European Patent Office
Prior art keywords
muteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18887098.4A
Other languages
English (en)
French (fr)
Other versions
EP3720470A1 (de
Inventor
Nathan HIGGINSON-SCOTT
Joanne L. Viney
Jyothsna Visweswaraiah
Erik Robert Sampson
Kevin Lewis Otipoby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pandion Operations Inc
Original Assignee
Pandion Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/109,875 external-priority patent/US10174091B1/en
Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc
Publication of EP3720470A1 publication Critical patent/EP3720470A1/de
Publication of EP3720470A4 publication Critical patent/EP3720470A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18887098.4A 2017-12-06 2018-11-28 Il-2 muteine und deren verwendung Pending EP3720470A4 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762595357P 2017-12-06 2017-12-06
US201862675972P 2018-05-24 2018-05-24
US201862721644P 2018-08-23 2018-08-23
US16/109,875 US10174091B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US16/109,897 US10174092B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
PCT/US2018/062808 WO2019112854A1 (en) 2017-12-06 2018-11-28 Il-2 muteins and uses thereof

Publications (2)

Publication Number Publication Date
EP3720470A1 EP3720470A1 (de) 2020-10-14
EP3720470A4 true EP3720470A4 (de) 2021-09-15

Family

ID=66751187

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18887098.4A Pending EP3720470A4 (de) 2017-12-06 2018-11-28 Il-2 muteine und deren verwendung

Country Status (11)

Country Link
EP (1) EP3720470A4 (de)
JP (1) JP7250790B2 (de)
KR (3) KR102687035B1 (de)
CN (2) CN118515780A (de)
AU (2) AU2018378078B2 (de)
BR (1) BR112020011343A2 (de)
CA (1) CA3083941A1 (de)
IL (1) IL274844A (de)
MX (1) MX2020005208A (de)
SG (1) SG11202003965VA (de)
WO (1) WO2019112854A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596108A4 (de) 2017-03-15 2020-12-23 Pandion Operations, Inc. Gezielte immuntoleranz
BR112019024127A2 (pt) 2017-05-24 2020-06-23 Pandion Therapeutics, Inc. Imunotolerância alvejada
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3720871A4 (de) * 2017-12-06 2021-09-15 Pandion Operations, Inc. Gezielte immuntoleranz
EP3972992A4 (de) 2019-05-20 2023-07-19 Pandion Operations, Inc. Gegen madcam gerichtete immuntoleranz
AU2020323893A1 (en) 2019-07-26 2022-02-17 Visterra, Inc. Interleukin-2 agents and uses thereof
US20210206856A1 (en) * 2019-08-19 2021-07-08 Pandion Therapeutics, Inc. Targeted immunotolerance with a pd-1 agonist
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
US20240158458A1 (en) 2019-10-15 2024-05-16 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
EP4077397A2 (de) 2019-12-20 2022-10-26 Regeneron Pharmaceuticals, Inc. Neuartige il-2-agonisten und verfahren zur verwendung davon
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN112358540A (zh) * 2020-11-03 2021-02-12 安徽环球基因科技有限公司 一种重组il2在毕赤酵母中的生产方法
JP2024502708A (ja) 2020-12-04 2024-01-23 ビステラ， インコーポレイテッド インターロイキン－２作用物質を使用する方法
WO2023165553A1 (zh) * 2022-03-03 2023-09-07 海南先声药业有限公司 IL2突变体-抗体Fc嵌段融合蛋白的药物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217989A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2020061142A1 (en) * 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1007907B (zh) * 1985-04-30 1990-05-09 弗·哈夫曼-拉罗彻有限公司 重组人类白细胞介素-2的提纯
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
EP2655409A4 (de) * 2010-12-22 2015-07-01 Univ Leland Stanford Junior Superagonisten und antagonisten von interleukin-2
CN103702721A (zh) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 Il-21表位和il-21配体
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN106795213B (zh) * 2014-07-21 2021-12-07 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的分子
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CN110382525B (zh) * 2017-04-03 2023-10-20 豪夫迈·罗氏有限公司 免疫缀合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217989A1 (en) * 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2020061142A1 (en) * 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019112854A1 *

Also Published As

Publication number Publication date
CA3083941A1 (en) 2019-06-13
AU2018378078A1 (en) 2020-06-18
KR102687035B1 (ko) 2024-07-22
KR20200097275A (ko) 2020-08-18
CN111432831A (zh) 2020-07-17
SG11202003965VA (en) 2020-06-29
EP3720470A1 (de) 2020-10-14
KR20240115352A (ko) 2024-07-25
KR102684426B1 (ko) 2024-07-11
JP7250790B2 (ja) 2023-04-03
IL274844A (en) 2020-07-30
CN111432831B (zh) 2024-08-16
AU2024216451A1 (en) 2024-09-26
CN118515780A (zh) 2024-08-20
WO2019112854A1 (en) 2019-06-13
MX2020005208A (es) 2020-08-20
BR112020011343A2 (pt) 2020-11-17
KR20240039201A (ko) 2024-03-26
JP2021507690A (ja) 2021-02-25
AU2018378078B2 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
EP3720470A4 (de) Il-2 muteine und deren verwendung
EP3733693A4 (de) Il-2-variante
EP3720502A4 (de) Cytobiologika und therapeutische verwendungen davon
EP3681888A4 (de) Pyrazolopyrimidinonverbindungen und verwendungen davon
EP3453401A4 (de) Interleukin-kombination und deren verwendung
EP3758778A4 (de) Medizinische vorrichtungen und verwendungen davon
EP3511407A4 (de) Christensenella intestinihominis und anwendung davon
EP3841096A4 (de) Pyridinylmethylenpiperidinderivate und deren verwendungen
EP3700934A4 (de) Verbindungen und verwendungen davon
EP3902530A4 (de) Polymere nanovakzine und verwendungen davon
EP3638251A4 (de) Bisphosphocingelformulierungen und verwendungen davon
EP3808357A4 (de) Zusammensetzung und verwendungen davon
EP3691629A4 (de) Nährstoffsporenformulierungen und deren verwendungen
EP3687501A4 (de) Iniparib-formulierungen und verwendungen davon
EP3762364A4 (de) Pyrrolidinamidderivate und verwendungen davon
EP3665191A4 (de) Braf-spezifische tcrs und verwendungen davon
EP3730565A4 (de) Mehrschichtstruktur und verwendungen davon
EP3683303A4 (de) Megamonas funiformis und verwendung davon
EP3856755A4 (de) Terpinoidderivate und verwendungen davon
EP3746077A4 (de) Parenterale formulierungen und verwendungen davon
EP3689887A4 (de) Zusammensetzung und lichtemittierende vorrichtung damit
EP3729351A4 (de) Schnelle und trennungsbeständige blockchains
EP3684796A4 (de) Succinat-regulierende polypeptide und deren verwendung
EP3635324A4 (de) Umkehreinfrierungszusammensetzungen und deren verwendung
EP3611181A4 (de) Auf atp1a1t abzielendes polypeptid und dessen verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VISWESWARAIAH, JYOTHSNA

Inventor name: SAMPSON, ERIK ROBERT

Inventor name: OTIPOBY, KEVIN LEWIS

Inventor name: VINEY, JOANNE L.

Inventor name: HIGGINSON-SCOTT, NATHAN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PANDION OPERATIONS, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039617

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/06 20060101ALI20210809BHEP

Ipc: A61P 37/04 20060101ALI20210809BHEP

Ipc: A61P 37/02 20060101ALI20210809BHEP

Ipc: A61P 29/00 20060101ALI20210809BHEP

Ipc: A61K 47/68 20170101ALI20210809BHEP

Ipc: A61K 38/20 20060101AFI20210809BHEP